Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts

被引:30
|
作者
Jacobi, Angela [1 ]
Thieme, Sebastian [1 ,2 ]
Lehmann, Romy [1 ]
Ugarte, Fernando [1 ]
Malech, Harry L. [3 ]
Koch, Sina [4 ]
Thiede, Christian [2 ,4 ]
Mueller, Katrin [4 ]
Bornhaeuser, Martin [2 ,4 ]
Ryser, Martin [1 ]
Brenner, Sebastian [1 ,2 ]
机构
[1] Univ Clin Carl Gustav Carus Dresden, Dept Pediat, D-01307 Dresden, Germany
[2] Tech Univ Dresden, DFG Res Ctr & Cluster Excellence Regenerat Therap, Dresden, Germany
[3] NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA
[4] Univ Clin Carl Gustav Carus Dresden, Med Clin 1, D-01307 Dresden, Germany
关键词
ACUTE MYELOGENOUS LEUKEMIA; PERIPHERAL-BLOOD; FLT3; MUTATIONS; FLT3-ACTIVATING MUTATIONS; HEMATOPOIETIC-CELLS; PROGENITOR CELLS; STEM-CELLS; SURVIVAL; ENGRAFTMENT; CHEMOTAXIS;
D O I
10.1016/j.exphem.2009.12.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Internal tandem duplication (ITD) mutations of the FLT3 receptor are associated with a high incidence of relapse in acute myeloid leukemia (AML). Expression of the CXCR4 receptor in FLT3-ITD-positive AML is correlated with poor outcome, and inhibition of CXCR4 was shown to sensitize AMI, blasts toward chemotherapy. The aim of this study was to evaluate the impact of FLT3-ITD on cell proliferation and CXCR4-dependent migration in human hematopoietic progenitor cells and to investigate their response to CXCR4 inhibition. Materials and Methods. We use primary blasts from patients with FLT3-ITD or FLT3 wild-type AML. In addition, human CD34(+) hematopoietic progenitor cells were transduced to >70% with retroviral vectors containing human FLT3-ITD. Results. We found that FLT3-ITD transgene overexpressing human hematopoietic progenitor cells show strongly reduced migration toward stromal-derived factor-1 in vitro and display significantly reduced bone marrow homing in nonobese diabetic severe combined immunodeficient mice. Cocultivation of FLT3-ITD-positive AML blasts or hematopoietic progenitor cells oil bone marrow stromal cells resulted in a strong proliferation advantage and increased early cobblestone area-forming cells compared to FLT3-wild-type AML blasts. Addition of the CXCR4 inhibitor AMD3100 to the coculture significantly reduced both cobblestone area-forming cells and proliferation of FLT3-ITD-positive cells, but did not affect FLT3-wild-type cells-highlighting the critical interaction between CXCR4 and FLT3-ITD. Conclusion. CXCR4 inhibition to decrease cell proliferation and to control the leukemic burden play provide a novel therapeutic strategy in patients with advanced FLT3-ITD-positive AML. (C) 2010 ISEH - Society for Hematology and Stern Cells. Published by Elsevier Inc.
引用
收藏
页码:180 / 190
页数:11
相关论文
共 50 条
  • [1] Inhibition of the Phosphatase STS1 in FLT3-ITD-Positive AML
    Zhang, J.
    Vakhrusheva, O.
    Thoelken, M.
    Brandts, C.
    ANNALS OF HEMATOLOGY, 2017, 96 : S55 - S55
  • [2] Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of FLT3-ITD-positive AML treated with gilteritinib
    Kondo, Takeshi
    Onozawa, Masahiro
    Fujisawa, Shinichi
    Harada, Shinpei
    Ogasawara, Reiki
    Izumiyama, Koh
    Saito, Makoto
    Morioka, Masanobu
    Mori, Akio
    Teshima, Takanori
    HEMATOLOGY, 2021, 26 (01) : 256 - 260
  • [3] NFATc1 as a therapeutic target in FLT3-ITD-positive AML
    S K Metzelder
    C Michel
    M von Bonin
    M Rehberger
    E Hessmann
    S Inselmann
    M Solovey
    Y Wang
    K Sohlbach
    C Brendel
    T Stiewe
    J Charles
    A Ten Haaf
    V Ellenrieder
    A Neubauer
    S Gattenlöhner
    M Bornhäuser
    A Burchert
    Leukemia, 2015, 29 : 1470 - 1477
  • [4] Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD-Positive AML
    Thomas, Megan E. Zavorka
    Lu, Xiyuan
    Talebi, Zahra
    Jeon, Jae Yoon
    Buelow, Daelynn R.
    Gibson, Alice A.
    Uddin, Muhammad Erfan
    Brinton, Lindsey T.
    Nguyen, Julie
    Collins, Meghan
    Lodi, Alessia
    Sweeney, Shannon R.
    Campbell, Moray J.
    Sweet, Douglas H.
    Sparreboom, Alex
    Lapalombella, Rosa
    Tiziani, Stefano
    Baker, Sharyn D.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (11) : 2207 - 2217
  • [5] Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML
    Wu, H.
    Wang, A.
    Qi, Z.
    Li, X.
    Chen, C.
    Yu, K.
    Zou, F.
    Hu, C.
    Wang, W.
    Zhao, Z.
    Wu, J.
    Liu, J.
    Liu, X.
    Wang, L.
    Wang, W.
    Zhang, S.
    Stone, R. M.
    Galinsky, I. A.
    Griffin, J. D.
    Weinstock, D.
    Christodoulou, A.
    Wang, H.
    Shen, Y.
    Zhai, Z.
    Weisberg, E. L.
    Liu, J.
    Liu, Q.
    LEUKEMIA, 2016, 30 (10) : 2112 - 2116
  • [6] NFATc1 as a therapeutic target in FLT3-ITD-positive AML
    Metzelder, S. K.
    Michel, C.
    von Bonin, M.
    Rehberger, M.
    Hessmann, E.
    Inselmann, S.
    Solovey, M.
    Wang, Y.
    Sohlbach, K.
    Brendel, C.
    Stiewe, T.
    Charles, J.
    Ten Haaf, A.
    Ellenrieder, V.
    Neubauer, A.
    Gattenloehner, S.
    Bornhaeuser, M.
    Burchert, A.
    LEUKEMIA, 2015, 29 (07) : 1470 - 1477
  • [7] Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML
    H Wu
    A Wang
    Z Qi
    X Li
    C Chen
    K Yu
    F Zou
    C Hu
    W Wang
    Z Zhao
    J Wu
    J Liu
    X Liu
    L Wang
    W Wang
    S Zhang
    R M Stone
    I A Galinsky
    J D Griffin
    D Weinstock
    A Christodoulou
    H Wang
    Y Shen
    Z Zhai
    E L Weisberg
    J Liu
    Q Liu
    Leukemia, 2016, 30 : 2112 - 2116
  • [8] Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML
    Cortes, Jorge
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [9] FLT3-ITD Allele Frequency Is an Independent Prognostic Factor for Poor Outcome in FLT3-ITD-Positive AML Patients
    Shafik, Nevine F.
    Darwish, Amira D.
    Allam, Rasha Mahmoud
    Elsayed, Ghada M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 676 - 685
  • [10] Midostaurin-induced Sweet syndrome in a patient with FLT3-ITD-positive AML
    Alkassis, Samer
    Rizwan, Aliza
    Daoud, Lina
    Chi, Jie
    BMJ CASE REPORTS, 2021, 14 (08)